Efficient Drug Delivery to Alveolar Macrophages and Lung Epithelial Lining Fluid Following Pulmonary Administration of Liposomal Ciprofloxacin in Rats with Pneumonia and Estimation of its Antibacterial Effects

REFERENCES

• T. C. Alba-Loureiro, E. F. Martins, R. G. Landgraf, S. Jancar, R. Curi, and P. Sannomiya. (2006). Role of insulin on PGE2 generation during LPS-induced lung inflammation in rats. Life Sci. 78:578–585.
   PubMed Web of Science ®Google Scholar
• D. Andes, and W. A. Craig. (2003). Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob. Agents Chemother. 47:3935–3941.
   PubMed Web of Science ®Google Scholar
• J. M. Antonini, and M. J. Reasor. (1991). Accumulation of amiodarone and desethylamiodarone by rat alveolar macrophages in cell culture. Biochem. Pharmacol. 42:S151–S156.
   PubMed Web of Science ®Google Scholar
• J. Blaser, B. B. Stone, M. C. Groner, and S. H. Zinner. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother 31:1054–1060.
   PubMed Web of Science ®Google Scholar
• H. Blau, K. Klein, I. Shalit, D. Halperin, and I. Fabian. (2007). Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am. J. Physiol. Lung Cell Mol. Physiol 292:L343–L352.
   PubMed Web of Science ®Google Scholar
• M. M. Branford. (1976). A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248–254.
   PubMed Web of Science ®Google Scholar
• S Chono, T Tanino, T Seki, and K. Morimoto. (2006). Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J. Drug Target 14:557–566.
   PubMed Web of Science ®Google Scholar
• S Chono, T Tanino, T Seki, and K. Morimoto. (2007). Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections. Drug Metab. Pharmacokinet 22:88–95.
   PubMed Web of Science ®Google Scholar
• S Chono, T Tanino, T Seki, and K. Morimoto. (2008). Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J. Control. Release 127:50–58.
   PubMed Web of Science ®Google Scholar
• W. A. Craig. (1995). Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis 22:89–96.
   PubMed Web of Science ®Google Scholar
• A. Dalhoff, and I. Shalit. (2003). Immunomodulatory effects of quinolones. Lancet Infect. Dis. 3:359–371.
   PubMed Web of Science ®Google Scholar
• P. Densen, and G. L. Mandell. (1980). Phagocyte strategy vs. microbial tactics. Rev. Infect. Dis 2:817–838.
   PubMedGoogle Scholar
• G. Ferrari, H. Langen, M. Naito, and J. Pieters. (1999). A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 14:435–447.
   Web of Science ®Google Scholar
• A. Forrest, D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother 37:1073–1081.
   PubMed Web of Science ®Google Scholar
• G. Greub, and D. Raoult. (2004). Microorganisms resistant to free-living amoebae. Clin. Microbiol. Rev 17:413–433.
   PubMed Web of Science ®Google Scholar
• O. S. Harb, L. Y. Gao, and Y. Abu Kwaik. (2000). From protozoa to mammalian cells: a new paradigm in the life cycle of intracellular bacterial pathogens. Environ. Microbiol 2:251–265.
   PubMed Web of Science ®Google Scholar
• S. J. Harnett, A. P. Fraise, J. M. Andrews, G. Jevons, N. P. Brenwald, and R. Wise. (2004). Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. J. Antimicrob. Chemother. 53:783–792.
   PubMed Web of Science ®Google Scholar
• M. A. Horwitz, and S. C. Silverstein. (1980). Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. J. Clin. Invest 65:82–94.
   PubMed Web of Science ®Google Scholar
• J. M. Hyatt, P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. (1995). The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet 28:143–160.
   PubMed Web of Science ®Google Scholar
• I. Ikaheimo, H. Syrjala, J. Karhukorpi, R. Schildt, and M. Koskela. (2000). In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J. Antimicrob. Chemother. 46:287–290.
   PubMed Web of Science ®Google Scholar
• T. Ishida, T. Hashimoto, M. Arita, I. Ito, and M. Osawa. (1998). Etiology of community-acquired pneumonia in hospitalized patients: A 3-year prospective study in Japan. Chest 114:1588–1593.
   PubMed Web of Science ®Google Scholar
• Y. Kohno, H. Yoshida, T. Suwa, and T. Suga. (1990). Uptake of clarithromycin by rat lung cells. J. Antimicrob. Chemother. 26:503–513.
   PubMed Web of Science ®Google Scholar
• D. P. Krieg, R. J. Helmke, V. F. German, and J. A. Mangos. (1988). Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro. Infect. Immun 56:3173–3179.
   PubMed Web of Science ®Google Scholar
• J. D. McKinney, Honer zu, K. Bentrup, E. J. Munoz-Elias, A. Miczak, B. Chen, W. T. Chan, D. Swenson, J. C. Sacchettini, W. R. JacobsJr., and D. G. Russell. (2000). Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406:735–738.
   PubMed Web of Science ®Google Scholar
• N. Miyashita, Y. Niki, T. Kishimoto, M. Nakajima, and T. Matsushima. (1997). In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob. Agents Chemother 41:1331–1334.
   PubMed Web of Science ®Google Scholar
• J. F. Mohr, P. S. McKinnon, P. J. Peymann, I. Kenton, E. Septimus, and P. C. Okhuysen. (2005). A restrospextive, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Phamacotherapy 25:1303–1309.
   PubMed Web of Science ®Google Scholar
• R. D. Moore, P. S. Lietman, and C. R. Smith. (2005). Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis 155:93–99.
   Google Scholar
• J. W. Mouton, M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. (2002). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int. J. Antimicrob. Agents 19:355–358.
   PubMed Web of Science ®Google Scholar
• J. W. Mouton, M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. (2005). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother 55:601–607.
   PubMed Web of Science ®Google Scholar
• H. C. Neu, W. Fang, J. W. Gu, and N. X. Chin. (1992). In vitro activity of OPC-17116. Antimicrob. Agents Chemother 36:1310–1305.
   PubMed Web of Science ®Google Scholar
• Y. Onodera, M. Tanaka, and K. Sato. (2001). Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 47:447–450.
   PubMed Web of Science ®Google Scholar
• T. Otani, M. Tanaka, E. Ito, Y. Kurosaka, Y. Murakami, K. Onodera, T. Akasaka, and K. Sato. (2003). In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob. Agents Chemother. 47:3750–3759.
   PubMed Web of Science ®Google Scholar
• Y. Otsu, K. Yanagihara, Y. Fukuda, Y. Miyazaki, K. Tsukamoto, Y. Hirakata, K. Tomono, J. Kadota, T. Tashiro, I. Murata, and S. Kohno. (2003). In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. Antimicrob. Agents Chemother. 47:3699–3703.
   PubMed Web of Science ®Google Scholar
• X. S. Pan, and L. M. Fisher. (1997). Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471–474.
   PubMed Web of Science ®Google Scholar
• L. Patmore, S. Fraser, D. Mair, and A. Templeton. (2000). Effect of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. Eur. J. Pharmacol 406:449–452.
   PubMed Web of Science ®Google Scholar
• P. K. Peterson, J. Verhoef, L. D. Sabath, and P. G. Quie. (1977). Effect of protein A on staphylococcal opsonization. Infect. Immun 15:760–764.
   PubMed Web of Science ®Google Scholar
• S. L. Preston, G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125–129.
   PubMed Web of Science ®Google Scholar
• S. I. Rennard, G. Basset, D. Lecossier, K. M. O'Donnell, P. Pinkston, P. G. Martin, and R. G. Crystal. (1986). Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60:532–538.
   PubMed Web of Science ®Google Scholar
• A. Safdar, and D. Armstrong. (2003). Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955–1997). J. Clin. Microbiol. 41:483–485.
   PubMed Web of Science ®Google Scholar
• H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel. (2003). Stretching the mutant prevention concentration (MPC) beyond its limits. J. Antimicrob. Chemother. 51:1323–1325.
   PubMed Web of Science ®Google Scholar
• H. G. Stiver, K. Zachidniak, and D. P. Speert. (1988). Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Clin. Invest. Med 11:247–252.
   PubMed Web of Science ®Google Scholar
• M. Takahata, J. Mitsuyama, Y. Yamashiro, M. Yonezawa, H. Araki, Y. Todo, S. Minami, Y. Watanabe, and H. Narita. (1999). In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob. Agents Chemother. 43:1077–1084.
   PubMed Web of Science ®Google Scholar
• P. Tattevin, T. Messiaen, V. Pras, P. Ronco, and M. Biour. (1998). Confusion and general seizures following ciprofloxacin administration. Nephrol. Dial. Transplant 13:2712–2713.
   PubMed Web of Science ®Google Scholar
• P. L. Toutain, J. R. del Castillo, and A. Bousquet-Melou. (2002). The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Res. Vet. Sci 73:105–114.
   PubMed Web of Science ®Google Scholar
• http://www.who.int/whr/2003/en/ World Health Organization. (2003). The world health report 2003 – shaping the future, from.
   Google Scholar